<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02261883</url>
  </required_header>
  <id_info>
    <org_study_id>RIV-PN-201</org_study_id>
    <nct_id>NCT02261883</nct_id>
  </id_info>
  <brief_title>Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn</brief_title>
  <official_title>Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study aims to assess the safety and treatment effect of acute dosing with IV
      Remodulin in neonates with persistent pulmonary hypertension of the newborn (PPHN).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll subjects with PPHN who do not show an adequate response to inhaled
      nitric oxide with the hypothesis that the addition of intravenous (IV) Remodulin will reduce
      the rate of clinical worsening as compared to standard of care. Additionally, this study aims
      to evaluate the treatment effect of Remodulin and better understand the dosing and
      pharmacokinetics in the neonatal population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the rate of clinical worsening in neonates with PPHN</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Efficacy will be assessed by a composite endpoint of clinical worsening as defined by the following:
Initiation of additional pulmonary vasodilator therapy
Initiation of extracorporeal mechanical oxygenation (ECMO) per institutional policies
Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to discontinuation of inhaled nitric oxide (iNO)</measure>
    <time_frame>Up to Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in oxygenation index (OI)</measure>
    <time_frame>Hour 12, hour 24, hour 72, Day 7 and Day 14/ or prior to study drug discontiuation</time_frame>
    <description>OI= [MAP(mmHg) x FiO2(%) / PaO2(mmHg)] x 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time on mechanical ventilation</measure>
    <time_frame>Up to Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to initiation of ECMO</measure>
    <time_frame>Up to Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean treprostinil plasma concentration per dose achieved</measure>
    <time_frame>24 hours after initiation of Remodulin and immediately prior to wean</time_frame>
    <description>Two blood samples will be collected from each patient for treprostinil pharmacokinetic (PK) analysis. Plasma samples will be analyzed for treprostinil using a validated bioanalytical plasma assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>up to Day 56</time_frame>
    <description>Assessment of adverse events, change in vital signs, and change in labs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in partial pressure of oxygen in arterial blood (PaO2) / fraction of inspired oxygen (FiO2) [P/F ratio]</measure>
    <time_frame>Hour 12, hour 24, and hour 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in N-terminal pro-Brain Natriuretic Peptide (NT-proBNP)</measure>
    <time_frame>Day 7, Day 14, prior to study drug wean, study drug discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pre and post-ductal oxygen saturation (SpO2)</measure>
    <time_frame>Hour 6, hour 12, hour 24, and hour 72</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Persistent Pulmonary Hypertension of the Newborn</condition>
  <arm_group>
    <arm_group_label>IV Remodulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Remodulin will be initiated at 1 ng/kg/min. The dose will be increased in up to 2 ng/kg/min increments every 2 hrs until the OI is &lt;10 (in the absence of dose-limiting side effects).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be initiated at 1 ng/kg/min. The dose will be increased in up to 2 ng/kg/min increments every 2 hrs until the OI is &lt;10 (in the absence of dose-limiting side effects).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Remodulin</intervention_name>
    <description>Treprostinil is a chemically stable tricyclic analogue of prostacyclin.</description>
    <arm_group_label>IV Remodulin</arm_group_label>
    <other_name>treprostinil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parent(s) or guardian provides consent for the subject to participate, as per
             institutional policy

          -  At least 2 kg at Screening

          -  Gestational age ≥ 34 weeks and ≤ 14 days old at Screening

          -  Diagnosis of PPHN, which is either idiopathic in nature or associated with the
             following: meconium aspiration syndrome (MAS), pneumonia, respiratory distress
             syndrome (RDS), sepsis, birth hypoxia, perinatal encephalopathy or unilateral
             congenital diaphragmatic hernia (CDH)

          -  Currently requiring ventilator support

          -  Receiving iNO with two OIs of 15 or greater separated by at least 30 minutes after
             receiving iNO for at least 3 hours

          -  Echocardiographic evidence of pulmonary hypertension with elevated right ventricle
             pressure

          -  Dedicated venous access for the administration of study drug (central line or
             peripherally inserted central venous catheter)

        Exclusion Criteria:

          -  Previous or concurrent use of a phosphodiesterase-5 inhibitor (PDE5i), endothelin
             receptor antagonist (ERA), or prostanoid

          -  Significant congenital heart disease (CHD) as detected by ECHO (excluding presence of
             minor defects such as small secundum atrial septal defect (ASD), minor valvular
             abnormalities, or expected transitional findings such as a patent foramen ovale (PFO),
             or patent ductus arteriosus (PDA). Subjects with small muscular, restrictive
             ventricular septal defect (VSD) may be enrolled

          -  Clinically significant, untreated active pneumothorax at Screening

          -  Evidence of clinically significant bleeding

          -  Necrotizing entercolitis; ≥ Bells stage II at Screening

          -  Uncontrolled hypotension; mean systemic pressures ≤ 35 mmHg at Screening.

          -  Uncontrolled coagulopathy and / or untreated thrombocytopenia; defined as &lt;50,000
             platelets /µL at Screening

          -  History of severe (Grade 3 or 4) intracranial hemorrhage

          -  Currently receiving ECMO or has immediate plans to initiate ECMO

          -  Expected duration on mechanical ventilation of less than 48 hours

          -  Life expectancy is less than two months or has a lethal chromosomal anomaly

          -  Contraindication to ECMO

          -  Bilateral congenital diaphragmatic hernia

          -  Active seizures at Screening

          -  Currently participating in another clinical drug study (excluding observational
             registries)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kristan Rollins, PharmD</last_name>
    <email>krollins@unither.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Toscano</last_name>
      <phone>602-406-5861</phone>
      <email>Denise.Toscano@DignityHealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Heather Mulroy</last_name>
      <phone>602-406-8772</phone>
      <email>Heather.Mulroy@DignityHealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Vinit Manuel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allen Harrison</last_name>
      <phone>501-364-7192</phone>
      <email>harrisonha@archildrens.org</email>
    </contact>
    <investigator>
      <last_name>Sherry Courtney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Tang</last_name>
      <phone>323-361-7299</phone>
      <email>shatang@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Philipe Friedlich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ofelia Vargas-Shiraishi</last_name>
      <phone>714-509-8735</phone>
      <email>ovargas@CHOC.ORG</email>
    </contact>
    <investigator>
      <last_name>John Clearly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry Chen</last_name>
      <phone>650-723-8922</phone>
      <email>hchen14@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Christine Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mallory Boutin</last_name>
      <phone>858-966-1700</phone>
      <phone_ext>3209</phone_ext>
      <email>mboutin@rchsd.org</email>
    </contact>
    <investigator>
      <last_name>Denise Suttner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon Zapata</last_name>
      <phone>202-476-4524</phone>
      <email>rzapata@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Mariam Said, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155-3009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anabel Rodriguez</last_name>
      <phone>786-624-2590</phone>
      <email>anabel.rodriguez@mch.com</email>
    </contact>
    <investigator>
      <last_name>Magaly Diaz-Barbosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jade Hanson</last_name>
      <phone>727-767-6468</phone>
      <email>Jade.hanson@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Alfred Asante-Korang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Schau</last_name>
      <phone>312-227-5024</phone>
      <email>mschau@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Nicolas Porta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kosair Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Nason</last_name>
      <phone>502-629-5038</phone>
      <email>jajohn14@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Dan Stewart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Melvin</last_name>
      <phone>443-287-1650</phone>
      <email>pmelvin2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Lewis Romer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Russo</last_name>
      <email>Alessandra.Russo@cardio.chboston.org</email>
    </contact>
    <investigator>
      <last_name>Mary Mullen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane White</last_name>
      <phone>734-615-7840</phone>
      <email>dfwhite@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Steven M Donn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center - Baston Children's Hospital</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Williams</last_name>
      <phone>601-815-3070</phone>
      <email>hbarth@umc.edu</email>
    </contact>
    <investigator>
      <last_name>Renate Savich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Holmes</last_name>
      <phone>816-983-6378</phone>
      <email>aholmes@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Eugenia Pallotto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3784</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marilyn Weindler</last_name>
      <phone>212-305-3677</phone>
      <email>mw289@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Usha Krishnan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Childrens Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Gutentag</last_name>
      <phone>614-355-6626</phone>
      <email>Julie.Gutentag@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Molly Ball, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth M Camacho, MSN, RN, CPN, CDE</last_name>
      <phone>682-885-3395</phone>
      <email>Beth.Camacho@cookchildrens.org</email>
    </contact>
    <investigator>
      <last_name>David Riley, MD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ananth Chandrasekaran</last_name>
      <phone>832-824-1553</phone>
      <email>axchand1@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Nidhy Varghese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health Systems(UVA)</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Thielen</last_name>
      <phone>434-243-9377</phone>
      <email>MJT3C@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Swanson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Sullivan</last_name>
      <phone>206-987-4558</phone>
      <email>Erin.sullivan@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Kendra Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Lane</last_name>
      <phone>414-337-7312</phone>
      <email>llane@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Girja Konduri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Steinhorn RH. Nitric oxide and beyond: new insights and therapies for pulmonary hypertension. J Perinatol. 2008 Dec;28 Suppl 3:S67-71. doi: 10.1038/jp.2008.158. Review.</citation>
    <PMID>19057613</PMID>
  </reference>
  <reference>
    <citation>Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med. 1997 Feb 27;336(9):597-604. Erratum in: N Engl J Med 1997 Aug 7;337(6):434.</citation>
    <PMID>9036320</PMID>
  </reference>
  <reference>
    <citation>Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA, Roy BJ, Keszler M, Kinsella JP. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med. 2000 Feb 17;342(7):469-74.</citation>
    <PMID>10675427</PMID>
  </reference>
  <reference>
    <citation>Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002 Mar 15;165(6):800-4.</citation>
    <PMID>11897647</PMID>
  </reference>
  <reference>
    <citation>Rubenfire M, McLaughlin VV, Allen RP, Elliott G, Park MH, Wade M, Schilz R. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest. 2007 Sep;132(3):757-63. Epub 2007 Mar 30. Erratum in: Chest. 2007 Nov;132(5):1721.</citation>
    <PMID>17400684</PMID>
  </reference>
  <reference>
    <citation>Hiremath J, Thanikachalam S, Parikh K, Shanmugasundaram S, Bangera S, Shapiro L, Pott GB, Vnencak-Jones CL, Arneson C, Wade M, White RJ; TRUST Study Group. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant. 2010 Feb;29(2):137-49. doi: 10.1016/j.healun.2009.09.005.</citation>
    <PMID>20022264</PMID>
  </reference>
  <reference>
    <citation>Levy M, Celermajer DS, Bourges-Petit E, Del Cerro MJ, Bajolle F, Bonnet D. Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension. J Pediatr. 2011 Apr;158(4):584-8. doi: 10.1016/j.jpeds.2010.09.025. Epub 2010 Oct 30.</citation>
    <PMID>21035821</PMID>
  </reference>
  <reference>
    <citation>Ivy DD, Claussen L, Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol. 2007 Mar 1;99(5):696-8. Epub 2007 Jan 10.</citation>
    <PMID>17317374</PMID>
  </reference>
  <reference>
    <citation>Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992 Jul 9;327(2):70-5.</citation>
    <PMID>1603138</PMID>
  </reference>
  <reference>
    <citation>Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol. 2004 Aug;44(2):209-14.</citation>
    <PMID>15243302</PMID>
  </reference>
  <reference>
    <citation>Wade M, Baker FJ, Roscigno R, DellaMaestra W, Hunt TL, Lai AA. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. J Clin Pharmacol. 2004 Jan;44(1):83-8.</citation>
    <PMID>14681345</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2013</study_first_submitted>
  <study_first_submitted_qc>October 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2014</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PPHN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Persistent Fetal Circulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treprostinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

